Cell therapy & Type 1 diabetes

The most physiological way to reach a normal level of glycaemia.


The Bioartificial Pancreas

The only route to bring cell therapy to reality in a safe manner.


The Bioartificial pancreas & cell confinement

Primordial to guarantee long term cell survival and function.


Biosid project

A bioartificial pancreas to treat type 1 diabetes: optimization of cell survival and function in preclinical and clinical phases.

MAILPAN® (MAcroencapsulation of PANcreatic Islets) is a prototype of bioartificial pancreas usable in the human designed to treat type 1 diabetic patients. The prototype was developed along different stages since 1996 and led to the creation of the SME called Defymed in 2011.

Last updates

BIOSID project obtained a one year extension for the development of the bioartificial pancreas MAILPANLast update : 12-15-2015

... Read more

BIOSID at the 5th EPITA Winter Symposium & 34th AIDPIT Workshop, January 25-27 2015, Innsbruck, AustriaLast update : 12-16-2014

... Read more

BIOSID at the 4rd AIDPIT & EPITA Joint Symposium- Innsbruck- Austria- 26-28th January 2014Last update : 02-21-2014

... Read more
Read all updates